These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 12089588)

  • 21. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 22. Syndication--value in numbers.
    Sanborn KT
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE54-6. PubMed ID: 12089590
    [No Abstract]   [Full Text] [Related]  

  • 23. Strategies for managing risk in equity.
    Tang CM
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE57-60. PubMed ID: 12089591
    [No Abstract]   [Full Text] [Related]  

  • 24. 2006: a stellar year for financing.
    Lawrence S
    Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
    [No Abstract]   [Full Text] [Related]  

  • 25. The changing attitude of European VCs.
    Mitchell P
    Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807
    [No Abstract]   [Full Text] [Related]  

  • 26. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 27. US venture capital for biotechnology.
    Dibner MD; Trull M; Howell M
    Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
    [No Abstract]   [Full Text] [Related]  

  • 28. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 29. Medical entrepreneurism: the current opportunity in America.
    Lexa FJ
    J Am Coll Radiol; 2004 Oct; 1(10):762-8. PubMed ID: 17411697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of biotechnology funding: An interview with venture capitalist Dennis Purcell. Interviewed by Elaine Musgrave.
    Purcell D
    Clin Transl Sci; 2009 Oct; 2(5):320-1. PubMed ID: 20443914
    [No Abstract]   [Full Text] [Related]  

  • 31. Public markets show signs of life.
    Mitchell P
    Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
    [No Abstract]   [Full Text] [Related]  

  • 32. The term sheet tango.
    Willey T; Parsigian D
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE29-30. PubMed ID: 12874974
    [No Abstract]   [Full Text] [Related]  

  • 33. Where the money is.
    Fitzgerald M
    Nat Biotechnol; 2006 Mar; 24(3):240-2. PubMed ID: 16525370
    [No Abstract]   [Full Text] [Related]  

  • 34. Chinese biotechs wrestle with transparency, cultural hurdles.
    Jia H; Tang F; Orelli B
    Nat Biotechnol; 2011 May; 29(5):377-8. PubMed ID: 21552225
    [No Abstract]   [Full Text] [Related]  

  • 35. The habits of successful bioentrepreneurs.
    Hodgson J; Ward M
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE3-5. PubMed ID: 12874969
    [No Abstract]   [Full Text] [Related]  

  • 36. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 37. The importance of angels in starting a US biotech venture.
    Sohl J
    Nat Biotechnol; 2005 Feb; 23(2):263-4. PubMed ID: 15724275
    [No Abstract]   [Full Text] [Related]  

  • 38. Tales of two medical startup companies.
    Bottles K
    Physician Exec; 2001; 27(5):80-2. PubMed ID: 12881911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 40. A reprise for collaborative financing in biotech.
    Ransom J
    Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.